Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients

Annals of Oncology

Volumn 12, Issue 10, 2001, Pages 1411-1415

  Misset, J L ^a   Vennin, Ph ^b   Chollet, Ph ^c   Pouillart, P ^d   Laplaige, Ph ^e   Frobert, J L ^f   Castera, D ^g   Fabro, M ^h   Langlois, D ⁱ   Cortesi, E ^j   Lucas, V ^k   Gamelin, E ^l   Laadem, A ^m   Otero, J ⁿ  

^a HÔPITAL PAUL BROUSSE   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c CENTRE JEAN PERRIN   (France)

^d INSTITUT CURIE   (France)

^e Clinique Saint Come et Saint Damien   (France)

^f CENTRE HOSPITALIER   (France)

^g Clinique Saint Pierre   (France)

^h CENTRE VAL D AURELLE   (France)

ⁱ Centre St Michel   (France)

^j POLICLINICO UMBERTO I   (Italy)

^k CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^l CENTRE PAUL PAPIN   (France)

^m CAC   (France)

ⁿ INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

more..

Author keywords

DACH platinum; Neurotoxicity

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PARAMETER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL; TIME; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 0035184467     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012556627852     Document Type: Article

References (19)

1. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers
2. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
3. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
4. A multicenter phase II study of oxaliplatin (OXA) as a single agent in platinum (PT) and/or taxanes (TX) pretreated advanced ovarian cancer (AOC) final results
5. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer
6. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
7. The clinical relevance of mismatch repair protein immunohistochemistry in ovarian cancer
8. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival
9. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin
10. A call for change in anticancer drug evaluation
11. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
12. Phase III randomized study of cisplatin vs. paclitaxel vs. cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer
13. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
14. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
15. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer
16. Experimental study of three platinum complexes: CDDP, CBDCA and 1-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes
17. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer
18. hMLH1 expression and cellular response of ovarian tumor cells to treatment with cytotoxic anticancer agents
19. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience